Aim In this study, we aim to investigate the efficacy of convalescent plasma (CP) according to blood groups (BGs) in the treatment of critically ill patients diagnosed with COVID-19. Materials and methods: 28 critically ill and laboratory-confirmed COVID-19 patients who were admitted to intensive care unit (ICU) of Sakarya University, Medical Faculty were included in the study. Patients were divided into 2 groups as anti-A Antibody (Ab) containing (BG O and B) and those not containing anti-A Ab (BG A and AB) CP received patients. Results: Among 28 patients, 13 patients received anti-A Ab containing CP (BG; B: 6, O: 7), 15 patients not containing anti-A Ab CP (BG; A: 13, AB: 2). Duration in ICU, the rates of mechanical ventilation (MV) support and vasopressor support, the case fatality rate and discharge rate were lower in patients received CP containing anti-A Ab than not containing anti-A Ab CP. However, only the difference in the rate of MV support achieved statistically significance (p=0.04) Conclusion: In our study, it was observed that the efficiency of CP without anti-A antibody was lower than that of plasma containing anti-A antibody, although it was not statistically significant. This result is thought to be due to the anti-A antibody's ability to block the ACE2 receptor. We believe that this hypothesis should be investigated in controlled studies with higher patient numbers.
Turk J Med Sci (Turkish journal of medical sciences)
Cited: 0 times